Vasodilators for primary Raynaud's phenomenon
نویسندگان
چکیده
منابع مشابه
Primary pulmonary hypertension in pregnancy; a role for novel vasodilators.
We describe the case of a 28-week pregnant woman presenting with severe primary pulmonary hypertension (PPH). She had an elective Caesarean section under general anaesthesia at 32 weeks gestation. Pulmonary artery pressures (PAP) measured from a pulmonary artery catheter before anaesthesia were in excess of 100 mm Hg. Intraoperative nitric oxide was used to reduce PAP. After the delivery of a h...
متن کاملCalcium channel blockers for primary Raynaud's phenomenon.
BACKGROUND Calcium channel blockers are the most commonly prescribed drugs for people with primary Raynaud's phenomenon. Primary Raynaud's phenomenon is a common condition characterised by an exaggerated vasospastic response to cold or emotion: classically the digits (fingers and toes) turn white, then blue, then red. This is an update of the review first published in 2014. OBJECTIVES To asse...
متن کاملVasodilators and primary pulmonary hypertension. Variability of long-term response.
Long-term response to vasodilator therapy was assessed in six patients with PPH. Following an acute trial, each patient was restudied after (1) two months of drug administration, (2) one month of abstinence from therapy, and (3) an additional two months of therapy. Three of six patients had no long-term reduction of PVR after treatment; one showed a progressive increase. Of the three patients w...
متن کاملVasodilators in the treatment of primary pulmonary hypertension.
The use of vasodilators to reduce vascular resistance is over a hundred years old. BALFOUR [1] recommends the use of nitrites as vascular stimulants "which dilate the peripheral vessels (arterioles) and so promote the flow blood". In the case of primary pulmonary hypertension (PPH), vaso-constriction is one of three factors that combine to increase resistance to blood flow through the lungs. Th...
متن کاملPulmonary vasodilators.
Pulmonary vasodilators are an important treatment for pulmonary arterial hypertension. They reduce pulmonary artery pressure; improve hemodynamic function; alter ventilation/perfusion matching in the lungs; and improve functional quality of life, exercise tolerance, and survival in patients with severe pulmonary arterial hypertension. This paper reviews the currently available pulmonary vasodil...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2021
ISSN: 1465-1858
DOI: 10.1002/14651858.cd006687.pub4